ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,542Medicare Part D Prescriptions Filled, Including Refills

Rank: 222 out of 1206

$393K Total Retail Price of All Prescriptions

Rank: 307 out of 1206

393 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
27% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Iowa
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

10% of this provider’s 393 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

1% of this provider’s 7,835 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$41 was the average price of a prescription from this provider, compared to $46 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Iowa
SIMVASTATIN 554 452 1 1
OMEPRAZOLE 539 443 2 3
LISINOPRIL 450 334 3 4
AMLODIPINE BESYLATE 339 334 4 6
LEVOTHYROXINE SODIUM 326 291 5 2
PRAVASTATIN SODIUM 261 233 6 21
METOPROLOL TARTRATE 260 214 7 9
ATORVASTATIN CALCIUM 256 212 8 13
FUROSEMIDE 232 216 9 5
POTASSIUM CHLORIDE 198 173 10 12
HYDROCODONE-ACETAMINOPHEN 178 150 S3 11 7
HYDROCHLOROTHIAZIDE 158 123 12 11
CITALOPRAM HBR 157 140 13 16
SERTRALINE HCL 145 107 14 22
METOPROLOL SUCCINATE 144 129 15 15
METFORMIN HCL ER 131 98 16 58
FENOFIBRATE 117 64 17 56
ALENDRONATE SODIUM 116 102 18 19
TRAMADOL HCL 113 95 19 17
LOSARTAN-HYDROCHLOROTHIAZIDE 113 101 19 60
ATENOLOL 112 96 21 14
ALLOPURINOL 101 64 22 24
JANTOVEN 98 86 23 95
WARFARIN SODIUM 95 83 24 8
LOSARTAN POTASSIUM 89 83 25 20
BENAZEPRIL HCL 82 78 26 39
ZOLPIDEM TARTRATE 80 70 27 25
GLIMEPIRIDE 80 73 27 34
METFORMIN HCL 78 71 29 10
ADVAIR DISKUS 72 59 30 55
AZITHROMYCIN 71 54 31 46
PROPRANOLOL HCL 68 47 32 92
GABAPENTIN 67 56 33 18
DIGOXIN 65 65 34 43
RANITIDINE HCL 64 29 35 23
LANTUS 64 55 35 38
LANSOPRAZOLE 64 56 35 128
PREDNISONE 61 33 38 28
TRIAMTERENE-HCTZ 58 56 39 33
NAMENDA 58 58 39 36
DONEPEZIL HCL 57 57 41 29
DOXYCYCLINE HYCLATE 57 41 41 103
TRAZODONE HCL 57 34 41 37
TAMSULOSIN HCL 56 56 44 26
CLOPIDOGREL 54 48 45 48
GLYBURIDE 54 43 R 45 69
CARVEDILOL 53 53 47 32
CRESTOR 53 41 47 30
RAMIPRIL 52 52 49 96
AMLODIPINE BESYLATE-BENAZEPRIL 52 48 49 76
NEXIUM 51 50 51 47
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 18, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.